In Brief: Bufferin low-dose caplets
This article was originally published in The Tan Sheet
Executive Summary
Bufferin low-dose caplets: Bristol-Myers Squibb plans to drop an FSI for its low-dose (81 mg) aspirin product in October, following an FSI that ran in newspapers on July 27 and included a $1-off coupon. The FSIs mark BMS' first advertising effort for the "adult regimen strength" Bufferin line extension. Launched to the trade in February, low-dose Bufferin, "designed specially for people on an aspirin regimen or as directed by your doctor," has a "pH sensitive enteric coating" that does not dissolve until it reaches the small intestine, the company says. A 140-count bottle retails for $5.49. Other Bufferin products are available in 325 mg (Regular Strength) and 500 mg (Extra Strength) dosages...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning